About Cellarity
Cellarity is a biotechnology company pioneering a novel approach to drug discovery by developing Cell State-Correcting therapeutics. The company addresses the limitations of traditional drug discovery, which is often constrained by human bias and unable to comprehensively map the complex cellular interactions that characterize disease cascades. Cellarity's proprietary multi-omics AI-powered platform reveals new biological pathways and enables the regulation of genetic switches to restore proper cell function. This innovative approach allows the company to develop game-changing therapeutics for a range of complex diseases. Their lead program, CLY-124, targets sickle cell disease. By focusing on correcting dynamic cell states rather than single targets, Cellarity aims to address diseases that have been difficult to treat with conventional methods. The company's platform integrates advanced AI and machine learning with comprehensive biological data to identify novel therapeutic interventions.
Mission & Story
Mission
Cellarity aims to solve complex diseases with medicines designed to correct the dynamic cell state
Clinical Focus
Medical conditions and clinical areas addressed by Cellarity.
Who It Serves
Milestones & Awards
Recent Milestones
Development of lead program CLY-124 for sickle cell disease
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.